LINC02381 Promoted Cell Viability and Migration via Targeting miR-133b in Cervical Cancer Cells.
LINC02381
RhoA
cell viability
cervical cancer
miR-133b
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
11
2019
accepted:
19
04
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
It has been proved that lncRNAs could function as CeRNA for miRNAs in tumor growth and metastasis for cervical cancer. This paper aims to identify the role of LINC02381 in cervical cancer cells. RT-qPCR was utilized to measure the expression levels of LINC02381 in cervical cancer tissues and cells. MTT, colony formation assay, transwell assay, RT-qPCR, and Western blotting were performed to investigate the roles of LINC02381 in cervical cancer cells. RegRNA 2.0 was used to predict the miRNA-binding sites of LINC02381. Luciferase reporter assay and RT-qPCR were employed to confirm the sponging effect between miR-133b and LINC02381. This study showed that LINC02381 was up-regulated in cervical cancer cells and acted as an oncogene in the development of cervical cancer. LINC02381 promoted cell viability and metastasis via sponging miR-133b. Moreover, miR-133b could target its downstream mediator of RhoA and inhibit its expression. Overall, our results indicated that LINC02381 functions as an oncogene in cervical cancer and could serve as a novel target for cervical cancer therapies in the future.
Sections du résumé
BACKGROUND
BACKGROUND
It has been proved that lncRNAs could function as CeRNA for miRNAs in tumor growth and metastasis for cervical cancer. This paper aims to identify the role of LINC02381 in cervical cancer cells.
MATERIALS AND METHODS
METHODS
RT-qPCR was utilized to measure the expression levels of LINC02381 in cervical cancer tissues and cells. MTT, colony formation assay, transwell assay, RT-qPCR, and Western blotting were performed to investigate the roles of LINC02381 in cervical cancer cells. RegRNA 2.0 was used to predict the miRNA-binding sites of LINC02381. Luciferase reporter assay and RT-qPCR were employed to confirm the sponging effect between miR-133b and LINC02381.
RESULTS
RESULTS
This study showed that LINC02381 was up-regulated in cervical cancer cells and acted as an oncogene in the development of cervical cancer. LINC02381 promoted cell viability and metastasis via sponging miR-133b. Moreover, miR-133b could target its downstream mediator of RhoA and inhibit its expression.
CONCLUSION
CONCLUSIONS
Overall, our results indicated that LINC02381 functions as an oncogene in cervical cancer and could serve as a novel target for cervical cancer therapies in the future.
Identifiants
pubmed: 32547232
doi: 10.2147/CMAR.S237285
pii: 237285
pmc: PMC7261661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3971-3979Informations de copyright
© 2020 Chen et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Biosci Biotechnol Biochem. 2014;78(11):1895-901
pubmed: 25104222
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6776-83
pubmed: 25400758
PLoS One. 2016 May 27;11(5):e0156274
pubmed: 27232880
Lancet. 2003 Jun 28;361(9376):2217-25
pubmed: 12842378
Oncotarget. 2016 Dec 13;7(50):83001-83016
pubmed: 27792998
Oncogene. 2012 Sep 6;31(36):4067-75
pubmed: 22179829
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Br J Cancer. 2006 Mar 27;94(6):776-80
pubmed: 16495913
Oncotarget. 2017 Jul 4;8(27):43768-43781
pubmed: 27487126
Cancer Res. 2011 Jan 1;71(1):3-7
pubmed: 21199792
Oncogene. 2000 May 25;19(23):2739-44
pubmed: 10851074
Int J Cancer. 1989 Apr 15;43(4):672-6
pubmed: 2467886
Cancer Lett. 2011 Jan 1;300(1):10-9
pubmed: 20965651
Int J Oncol. 2011 Aug;39(2):311-8
pubmed: 21573504
Mol Cancer Res. 2015 Feb;13(2):330-8
pubmed: 25253741
Cancer Res. 2011 May 1;71(9):3246-56
pubmed: 21430067
Tumour Biol. 2016 Mar;37(3):2779-88
pubmed: 26715267
Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3187-93
pubmed: 26400521
Cell Physiol Biochem. 2016;40(1-2):219-229
pubmed: 27855392
PLoS One. 2014 Jul 09;9(7):e100340
pubmed: 25007342
Cancer Biol Ther. 2016;17(1):104-13
pubmed: 26574780
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Clin Cancer Res. 2004 Jul 15;10(14):4799-805
pubmed: 15269155
FEBS Lett. 2014 Apr 2;588(7):1168-77
pubmed: 24613927
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Bioinformatics. 2013 Sep 1;29(17):2221-2
pubmed: 23793747
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Tumour Biol. 2015 Sep;36(10):7615-22
pubmed: 25921283
Int J Cancer. 2010 Dec 15;127(12):2804-14
pubmed: 21351259
Med Oncol. 2017 May;34(5):98
pubmed: 28425074
Cell Death Dis. 2013 Aug 08;4:e760
pubmed: 23928699
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7
pubmed: 18760711
Dev Cell. 2013 Apr 15;25(1):69-80
pubmed: 23541921
Oncol Rep. 2014 Apr;31(4):1839-45
pubmed: 24573322
Cell Death Dis. 2014 Jun 12;5:e1287
pubmed: 24922071
Br J Cancer. 2003 Jan 13;88(1):63-73
pubmed: 12556961
Cancer Lett. 2016 May 1;374(2):261-71
pubmed: 26898939